Points to consider on the non-clinical safety evaluation of anticancer drugs.
Since malignant tumors are life-threatening, the death rate from these diseases is high, and existing therapies have limited effectiveness, it is desired to provide new effective anticancer drugs to tumor patients sooner. However, there is no guideline regarding non-clinical safety studies on the development of anticancer drugs required for the first in human clinical trials and for the approval applications in Japan. Then, the Ministry of Health, Labour and Welfare (MHLW) established the collaboration group including regulatory, academic and industrial scientists to prepare the guideline on the non-clinical safety evaluation of anticancer drugs in 2004. As a guide for basic concept of non-clinical safety studies on anticancer drugs, the "Points to Consider" document was prepared by this group in 2007.
Nakae
Dai
D
Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Onodera
Horoshi
H
Fueki
Osamu
O
Urano
Tsutomu
T
Komiyama
Noriyuki
N
Sagami
Fumio
F
Kai
Shuichi
S
Nishimura
Chihiro
C
Inoue
Tohru
T
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D018675:Toxicity Tests
D000970:Antineoplastic Agents